title: Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline.
abstract: Schistosomiasis, one of 17 diseases deemed to be neglected by the World Health Organization, has received little attention from the biopharmaceutical industry. Due to this, only a handful of drugs have been developed to treat schistosomiasis, with only one, praziquantel, used in most endemic regions. Growing concern over resistance coupled with praziquantel's incomplete efficacy across all stages of the Schistosoma platyhelminth life cycle highlights the urgent need for new drugs. The WIPO Re:Search consortium is a platform whereupon biopharmaceutical company compounds are being repurposed to efficiently and cost-effectively develop new drugs for neglected diseases such as schistosomiasis. This article summarizes recent clinical-stage efforts to identify new antischistosomals and highlights biopharmaceutical company compounds with potential for repurposing to treat schistosomiasis.
authors.affiliation: BIO Ventures for Global Health, 401 Terry Avenue North, Seattle, WA 98109, USA.
authors.forename: Roopa
authors.initials: R
authors.lastname: Ramamoorthi
authors.forename: Katy M
authors.initials: KM
authors.lastname: Graef
authors.forename: Jennifer
authors.initials: J
authors.lastname: Dent
mesh_terms: D000818:Animals; D000871:Anthelmintics / Q000191:economics / Q000494:pharmacology*; D003362:Cost-Benefit Analysis; D058492:Drug Repositioning / Q000191:economics / Q000379:methods; D006801:Humans; D058069:Neglected Diseases / Q000188:drug therapy* / Q000191:economics; D012547:Schistosoma / Q000187:drug effects*; D012552:Schistosomiasis / Q000188:drug therapy* / Q000191:economics
chemical_list: D000871:Anthelmintics